This study forms part of the first complete characterization of the dose-response curve for glycopyrrolate (GP) delivered using Co-Suspension™ Delivery Technology via a metered dose inhaler (MDI). We examined the lower GP MDI dose range to determine an optimal dose for patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD / Fabbri, Leonardo; Kerwin, Edward M; Spangenthal, Selwyn; Ferguson, Gary T; Rodriguez Roisin, Roberto; Pearle, James; Sethi, Sanjay; Orevillo, Chad; Darken, Patrick; St Rose, Earl; Fischer, Tracy; Golden, Michael; Dwivedi, Sarvajna; Reisner, Colin. - In: RESPIRATORY RESEARCH. - ISSN 1465-993X. - 17:1(2016), pp. 109-119. [10.1186/s12931-016-0426-4]
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD
FABBRI, Leonardo;
2016
Abstract
This study forms part of the first complete characterization of the dose-response curve for glycopyrrolate (GP) delivered using Co-Suspension™ Delivery Technology via a metered dose inhaler (MDI). We examined the lower GP MDI dose range to determine an optimal dose for patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
| File | Dimensione | Formato | |
|---|---|---|---|
|
s12931-016-0426-4.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
903.53 kB
Formato
Adobe PDF
|
903.53 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
